Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Al Razi Medical CoSAU:9572 -2.88%45 EBITDA Margin % is 7.62% as of Dec. 2025, which is 8% below its 10-year median of 8.25. GuruFocus rates SAU:9572 with a GF Score™ of 45/100 and a GF Value™ of ﷼64.45 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 664 Healthcare Providers & Services companies, Al Razi Medical Co ranks worse than 58.13% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Al Razi Medical Co's EBITDA for the
six
months ended in Dec. 2025 was ﷼3.08 Mil. Al Razi Medical Co's Revenue for the
six
months ended in Dec. 2025 was ﷼40.40 Mil. Therefore, Al Razi Medical Co's EBITDA margin for the quarter that ended in Dec. 2025 was 7.62%.
Al Razi Medical Co (SAU:9572) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Al Razi Medical Co EBITDA Margin % Related Terms
Al Razi Medical Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Al Razi Medical Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Al Razi Medical Co EBITDA Margin % Competitor Comparison
For the Pharmaceutical Retailers subindustry, Al Razi Medical Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Al Razi Medical Co EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Al Razi Medical Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Al Razi Medical Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Al Razi Medical Co (SAU:9572) has a EBITDA Margin % of 7.62% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Al Razi Medical Co and its competitors. This is near median its historical median of 8.25. Over the past decade, Al Razi Medical Co's EBITDA Margin % has ranged from 7.40 to 10.07. According to the industry distribution chart, Al Razi Medical Co ranks #386 out of 664 companies in the Healthcare Providers & Services industry, placing it in the top 58.1%.
Is Al Razi Medical Co's EBITDA Margin % too high?
Al Razi Medical Co's current EBITDA Margin % of 7.62% is near median its 10-year median of 8.25. Over the past 10 years, this metric has ranged from a low of 7.40 to a high of 10.07. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. Al Razi Medical Co's value of 7.62% is 25.4% below this industry median. Based on the distribution chart, Al Razi Medical Co ranks #386 out of 664 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Al Razi Medical Co has a GF Score™ of 45/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Al Razi Medical Co's EBITDA Margin % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Al Razi Medical Co ranks #386 out of 664 companies for EBITDA Margin %. This places Al Razi Medical Co in the lower half of its industry. The industry median EBITDA Margin % is 10.21. Al Razi Medical Co's value of 7.62% is 25.4% below this benchmark. Historically, Al Razi Medical Co's own EBITDA Margin % has ranged from 7.40 to 10.07 over the past decade. While the company's 10-year median is 8.25 vs. the industry median of 10.21, Al Razi Medical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 664 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Al Razi Medical Co's current EBITDA Margin % of 7.62% is 25.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Al Razi Medical Co and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Al Razi Medical Co's current EBITDA Margin % is 7.62%, which is near median its own 10-year median of 8.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Al Razi Medical Co stock overvalued right now?
Based on GuruFocus' analysis, Al Razi Medical Co (SAU:9572) is currently considered Significantly Undervalued. The stock's GF Value™ is ﷼64.45, compared to a current price of ﷼30.32 — trading 53% below its estimated fair value. The current EBITDA Margin % is 7.62%, which is near median its 10-year median of 8.25 and 25.4% below the Healthcare Providers & Services industry median of 10.21. Al Razi Medical Co's overall GF Score™ is 45/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Al Razi Medical Co (SAU:9572), the current EBITDA Margin % is 7.62% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Al Razi Medical Co (SAU:9572) Overvalued in 2026?
Based on GuruFocus' analysis, Al Razi Medical Co stock appears to be undervalued.
The current stock price of ﷼30.32 is trading 53% below its estimated GF Value™ of ﷼64.45.
GuruFocus considers Al Razi Medical Co to be Significantly Undervalued.
Key valuation signals for SAU:9572:
EBITDA Margin %: 7.62% (near median its 10-year median of 8.25)
GF Value™: ﷼64.45 vs. price of ﷼30.32 (53% below fair value)
Industry Position: 25.4% below the Healthcare Providers & Services median (#386 of 664)
No single metric tells the full story. See the SAU:9572 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Al Razi Medical Co operates in the medical field in the Kingdom of Saudi Arabia. The company provides all pharmaceutical and cosmetic products. It engages in buying and selling pharmaceuticals, medical supplies, herbal and cosmetic products, and all related products on a wholesale and retail basis.
45GF Score
Get the complete analysis for SAU:9572
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SAU:9572 has been successfully added to your 
